



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 09/13/2023 10:56 Received: 09/13/2023 10:56

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) FACS Assay, Positive, H, Negative, MMRL.

Screen positive, see confirmatory test results.

-----ADDITIONAL INFORMATION-----
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Test Performed by:
Mayo Clinic Laboratories - Rochester Main Campus
200 First Street SW, Rochester, MN 55905
Lab Director: William G. Morice M.D. Ph.D.; CLIA# 24D0404292

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: MOG FACS Titer, S, Positive 1:40, H, <1:20, titer, MMRL.

Caution advised. MOG-IgG has an overall specificity of 98%, but MOG-IgG at this level of 1:20 or 1:40 is considered low positive by the 2023 MOG antibody-associated disease (MOGAD) diagnostic criteria and has a positive predictive value as low as 50% for MOGAD. Up to half of those with MOG-IgG titers of 1:20 or 1:40 will have an alternative neurological disorder (e.g., MS) and care is needed to ensure the phenotype is characteristic. * MOGAD is a monophasic or relapsing CNS demyelinating disease that may affect any age with children particularly predisposed. Clinical manifestations include optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica or unilateral cortical encephalitis. A progressive course does not occur, CSF oligoclonal bands are rare (<15%) and MOGAD MRI lesions often differ in morphology and evolution from MS. Repeat MOG-IgG testing 6-12 months after disease onset may assist prognosis as persistence increases the risk of relapsing disease over a monophasic disorder. * References: Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: International MOGAD Panel Proposed Criteria. Lancet Neurol. 2023 Mar; 22(3): 268-282.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 09/13/2023 10:56 Received: 09/13/2023 10:56

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Sechi E, Buciu M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, Budhram A, Weinshenker BG, Lopez-Chiriboga AS, Tillema JM, McKeon A, Mills JR, Tobin WO, Flanagan EP. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol. 2021 Jun 1; 78(6): 741-74.

-----ADDITIONAL INFORMATION-----
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Test Performed by:
Mayo Clinic Laboratories - Rochester Main Campus
200 First Street SW, Rochester, MN 55905
Lab Director: William G. Morice M.D. Ph.D.; CLIA# 24D0404292

Performing Site:
MMRL: MAYO MEDICAL REFERENCE LAB 3050 Superior Drive NW Rochester MN 55901

Reported Date: 2023.09.13 10:57 MOGF

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED